FOR PROVIDERS

Mitigating the Complexities of Multiple Sclerosis

With precise, personalized results, the Octave MSDA test provides clinical data to support informed care decisions.

Establishing a Baseline Benchmark

Across all clinical scenarios, clinicians need a starting point. The MSDA Test delivers a measurable baseline to inform and track care over time.

Routine Care
Use routine visits to establish a baseline and personalize ongoing care decisions with objective data.
Presenting or Silent Symptoms
A baseline helps distinguish change from stability, whether symptoms are new, worsening, or absent.
Life Changes
Significant life events, such as pregnancy, aging, or comorbidities, can influence MS management. Establishing a baseline provides a reference point to assess how these changes may impact disease activity.

The Octave® MSDA Test

The Octave® Multiple Sclerosis Disease Activity Test (MSDA) Test is the first and only analytically and clinically validated multi-analyte biomarker for MS.

Personalized Reporting
Superior Results
Easy & Affordable

AI Enabled, Personalized Report.

Each report indicates a disease activity score, comprised of 18 biomarkers with 4 biological pathways, reflecting both the likelihood and severity of disease activity.

A longitudinal view of score history is also included, increasing clinician confidence in disease assessment over time.

The Octave MSDA test outperforms a single biomarker, NfL, in assessing three key disease activity measures: Gd+ lesions, new and enlarging T2 lesions, and active vs. stable status.¹

Order the MSDA test with ease

The Octave MSDA Test is easy to prescribe and accessible.

The Octave Cares program provides predictable financial assistance, with most patient financial responsibility $100 or less, ensuring broader access without financial uncertainty.

MSDA Test Use Cases

Discover how the MSDA Test is used in clinical practice to initiate, switch or discontinue DMTs

DMT Initiation

The MSDA Test identified elevated disease activity, supporting initiation of DMT in a newly diagnosed patient.

DMT Switching

The MSDA Test detected increased disease activity, providing objective evidence to support a change in DMT.

Commonly asked questions

Is the MSDA Test analytically and clinically validated?

answer

How do I speak with an expert to learn more?

answer

How can I implement the MSDA Test within my clinic?

answer

Does the MSDA Test measure progression?

answer

Ready to get started?

Speak with our clinical support team to learn more about implementing the MSDA Test.

The Octave Bioscience Clinical Laboratory is certified under the Clinical Laboratory Improvement Act of 1988 (CLIA) as qualified to perform high complexity clinical testing and is a College of American Pathology (CAP) Accredited Laboratory.

CLIA ID #05D2168340

Chitnis, Tanuja, et al. “Clinical Validation of a Multi-Protein, Serum-Based Assay for Disease Activity Assessments in Multiple Sclerosis.” Clinical Immunology, vol. 253, 2023, p. 109688. ScienceDirect, https://doi.org/10.1016/j.clim.2023.109688.

Mitigating the Complexities of Multiple Sclerosis

Establishing a Baseline Benchmark

The Octave® MSDA Test​​

The Octave® Multiple Sclerosis Disease Activity Test (MSDA) Test is the first and only analytically and clinically validated multi-analyte biomarker for MS.

AI Enabled, Personalized Report.

Each report indicates a disease activity score, comprised of 18 biomarkers with 4 biological pathways, reflecting both the likelihood and severity of disease activity.A longitudinal view of score history is also included, increasing clinician confidence in disease assessment over time.

The Octave MSDA test outperforms a single biomarker, NfL, in assessing three key disease activity measures: Gd+ lesions, new and enlarging T2 lesions, and active vs. stable status.1

Order the MSDA test with ease

The Octave MSDA Test is easy to prescribe and accessible.

The Octave Cares program provides predictable financial assistance, with most patient financial responsibility $100 or less, ensuring broader access without financial uncertainty.

MSDA Test Use Cases

Discover how the MSDA Test is used in clinical practice to initiate, switch or discontinue DMTs

DMT Initiation

The MSDA Test identified elevated disease activity, supporting initiation of DMT in a newly diagnosed patient.

DMT Switching

The MSDA Test detected increased disease activity, providing objective evidence to support a change in DMT.

Commonly asked questions

Ready to get started?

The Octave Bioscience Clinical Laboratory is certified under the Clinical Laboratory Improvement Act of 1988 (CLIA) as qualified to perform high complexity clinical testing and is a College of American Pathology (CAP) Accredited Laboratory.

CLIA ID #05D2168340

The Octave® MSDA Test

Each report indicates a disease activity score, comprised of 18 biomarkers with 4 biological pathways, reflecting both the likelihood and severity of disease activity.

A longitudinal view of score history is also included, increasing clinician confidence in disease assessment over time.

The Octave MSDA test outperforms a single biomarker, NfL, in assessing three key disease activity measures: Gd+ lesions, new and enlarging T2 lesions, and active vs. stable status.¹